Oggi sono 100 anni dalla nascita di Jan Karski
Il tempo a Roma
Takeda Pharmaceutical Co.
La società si focalizza su queste patologie: ulcera peptica, cancro alla prostata ed endometriosi, malattie urologiche, diabete e ipertensione, malattie respiratorie e infiammatorie, trattamento del dolore.
Takeda Pharmaceuticals è attiva anche nell'oncologia con una società indipendente,
Takeda ha 2 basi principali in Giappone a Osaka e Tokyo. La sua sede Americana si trova a Deerfield, Illinois, mentre quella Europea si trova a Zurigo, Svizzera.
I principali centri di ricerca si trovano a Osaka e Tsukuba, Giappone; San Diego, California; San Francisco, California; Cambridge, Regno Unito; e Singapore.
Gli stabilimenti produttivi sono 18 distribuiti in quattro continenti. (fonte: Wikipedia)
Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda® (lurasidone) - a New Atypical Antipsychotic Medication for Adults with SchizophreniaDainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan) today jointly announced that the European Commission has granted Marketing Authorization for once-daily oral Latuda® (lurasidone) for the treatment of schizophrenia in adults. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for Latuda on January 23, 2014. (PR Newswire - 28/03/2014) Leggi
Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's DiseaseTakeda submitted a Marketing Authorisation Application (MAA) to the EMA in March 2013 for vedolizumab for the treatment of adults with moderately to severely active UC or CD. The CHMP Opinion for vedolizumab will now be reviewed by the European Commission (EC). If the CHMP recommendation is formally adopted by the EC, vedolizumab would be approved for marketing in the 28 member states of the European Union as well as Norway, Iceland and Liechtenstein. (PR Newswire - 21/03/2014) Leggi
In this role he will be responsible for leading the continued expansion of Takeda's commercial activities in this region, which comprises Russia-CIS, Latin America, Middle East/Africa and South Asia. (PR Newswire - 18/03/2014) Leggi
Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with SchizophreniaThe Positive CHMP Opinion was based on a comprehensive clinical trial program which included placebo and active comparators. Lurasidone was shown to be effective in treating both positive and negative symptoms in acutely psychotic patients with schizophrenia over 6 weeks.,,,,In short and longer term clinical studies, lurasidone has demonstrated effectiveness with low rates of metabolic change.,, It is important to minimize the adverse effect of treatments on long-term physical health as patients are likely to remain on therapy for many years. (PR Newswire - 24/01/2014) Leggi
Takeda Pharmaceutical Company Limited (Takeda) ha anunciado que ha decidido finalizar voluntariamente las actividades de desarrollo de fasiglifam (TAK-875), un tratamiento en fase de investigación para la diabetes de tipo 2, debido a problemas en la seguridad hepática. (Business Wire - 27/12/2013) Leggi